Emma Eckernas
Overview
Explore the profile of Emma Eckernas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
37
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eckernas E, Macan-Schonleben A, Andresen-Bergstrom M, Birgersson S, Hoffmann K, Ashton M
Xenobiotica
. 2023 Nov;
53(8-9):515-522.
PMID: 37916667
-dimethyltryptamine (DMT) is a psychedelic compound that has shown potential in the treatment of depression. Aside from the primary role of monoamine oxidase A (MAO-A) in DMT metabolism, the metabolic...
2.
Luan L, Eckernas E, Ashton M, Rosas F, Uthaug M, Bartha A, et al.
J Psychopharmacol
. 2023 Oct;
38(1):56-67.
PMID: 37897244
N,N-Dimethyltryptamine (DMT) is a serotonergic psychedelic that induces a rapid and transient altered state of consciousness when inhaled or injected via bolus administration. Its marked and novel subjective effects make...
3.
Eckernas E, Koomen J, Timmermann C, Carhart-Harris R, Roshammar D, Ashton M
CPT Pharmacometrics Syst Pharmacol
. 2023 Sep;
12(10):1398-1410.
PMID: 37675853
N,N-dimethyltryptamine (DMT) is a psychedelic compound that is being studied as a therapeutic option in various psychiatric disorders. Due to its short half-life, continuous infusion of DMT has been proposed...
4.
Singleton S, Timmermann C, Luppi A, Eckernas E, Roseman L, Carhart-Harris R, et al.
bioRxiv
. 2023 May;
PMID: 37214949
Psychedelics offer a profound window into the functioning of the human brain and mind through their robust acute effects on perception, subjective experience, and brain activity patterns. In recent work...
5.
Tannergren C, Jadhav H, Eckernas E, Fagerberg J, Augustijns P, Sjogren E
Eur J Pharm Biopharm
. 2023 Apr;
186:144-159.
PMID: 37028605
Colon absorption is a key determinant for successful development of extended release and colon targeted drug products. This is the first systematic evaluation of the ability to predict in vivo...
6.
Eckernas E, Timmermann C, Carhart-Harris R, Roshammar D, Ashton M
CPT Pharmacometrics Syst Pharmacol
. 2023 Feb;
12(4):474-486.
PMID: 36762714
N,N-dimethyltryptamine (DMT) is a psychedelic substance and is being used as a research tool in investigations of the neurobiology behind the human consciousness using different brain imaging techniques. The effects...
7.
Eckernas E, Timmermann C, Carhart-Harris R, Roshammar D, Ashton M
Clin Transl Sci
. 2022 Sep;
15(12):2928-2937.
PMID: 36088656
N,N-dimethyltryptamine (DMT) is a psychedelic compound that is believed to have potential as a therapeutic option in several psychiatric disorders. The number of clinical investigations with DMT is increasing. However,...
8.
Eckernas E, Bendrioua A, Cancellerini C, Timmermann C, Carhart-Harris R, Hoffmann K, et al.
J Pharm Biomed Anal
. 2022 Feb;
212:114642.
PMID: 35149418
A highly sensitive LC-MS/MS method for the quantification of N,N-dimethyltryptamine (DMT) and its metabolites indole-3-acetic acid and DMT N-oxide in human plasma has been developed and validated. Chromatography was performed...
9.
Eckernas E, Tannergren C
Mol Pharm
. 2021 Mar;
18(4):1699-1710.
PMID: 33720733
Colon absorption is a key determinant for the successful development of modified-release (MR) formulations, and the risk that colon absorption may limit the in vivo performance of an MR product...